N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=39 Allergic Rhinitis Changes the Sinus Microbiome
Seasonal Allergic Rhinitis
Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391
Phase 4 N=41 NasoNeb Delivery of an Intranasal Steroid
Perennial Allergic Rhinitis
Primary: Change in Nasal Peak Inspiratory Flow (NPIF) — 36.41; 18.71 liters/min
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
N/A N=93 Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen
Allergic Rhinitis · Asthma · Latent Tuberculosis
Primary: IFN-y Protein Response in Mucosal Lining Fluid — NA; 3.29; 9.42; 8.20 pg/hr/ml
Phase 3 N=607 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.3; -3.3; -3.8; -2.2 units on a scale
Phase 3 N=832 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS) — -5.6; -4.7; -4.2; -2.9 units on a scale
Phase 3 N=536 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days — 17.98; 18.48; -1.97; -3.53 Scores on a scale — p=<0.001
Phase 3 N=703 A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
Perennial Allergic Rhinitis
Primary: Change From Baseline on Direct Visual Nasal Exams to 12 Months — 466; 237; 456; 229 Participants
Phase 3 N=581 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
Perennial Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days. — 14.7; 15.5; 15.8; -3.1 Scores on a Scale — p=0.03
Phase 3 N=1,791 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.5; -4.8; -4.9; -3.4 units on a scale
Phase 3 N=776 A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS) — -5.5; -4.5; -4.6; -3.0 units on a scale
Phase 3 N=333 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)
Allergic Rhinitis
Primary: Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.71; -0.40 Units on a scale — p=<0.001
N/A N=40 Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
Seasonal Allergic Rhinitis
Primary: Global Assessment — 1.7; 1.4 units on a scale — p=0.372
Phase 3 N=481 A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined)at 14 Days — 17.72; 17.74; -2.55; -3.60 scores on a scale — p=0.005
Phase 3 N=526 A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo — 17.86; 18.29; 17.83; -2.36 total…
Phase 3 N=506 A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
Seasonal Allergic Rhinitis
Primary: Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days — 18.76…
Phase 4 N=15 Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen
Allergic Rhinitis
Primary: Change in Tryptase Level From Baseline to Post-antigen Challenge — 0; 2.31 mcg/L — p=0.33
Phase 3 N=351 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days — -0.64; -0.49 Units on a scale — p=0.006
N/A N=10 Acupuncture for Nasal Congestion in Allergic Rhinitis
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
N/A N=13 Intranasal CO2 for Allergic Rhinitis
Allergic Rhinitis
Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams
Early Phase 1 N=21 Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
Rhinitis, Allergic, Seasonal
Primary: Change From Baseline in the Total Nasal Symptom Score (TNSS) at 15 Minutes After the First Allergan Challenge — 2.90; 3.69 units on a scale — p=0.156
Phase 2 N=70 Intranasal SB-705498 in Allergic Rhinitis (AR) Patients
Rhinitis
Primary: Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8 — 6.53; 3.65; 6.57; 4.14 Score on scale
Phase 2 N=47 Effects of Broccoli Sprout Extract on Allergy Rhinitis
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Phase 3 N=324 Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
Allergic Rhinitis
Primary: The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days. — -0.68; -0.57 Units on a scale — p=0.102
Phase 4 N=130 Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
Seasonal Allergic Rhinitis
Primary: Mean Percent Change in Reflective Total Nasal Symptom Score (rTNSS) From Baseline — -45.37; -47.35 Percent change
Phase 4 N=188 Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Rhinitis, Allergic, Seasonal · Asthma
Primary: Change From Baseline in Morning (AM) and Evening (PM) Total Asthma Symptom Severity (TASS) — 6.5; 5.9; -0.9; -1.4 Score on a scale — p=0.101
Phase 3 N=20 Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)
Allergic Rhinitis
Primary: Change in Sneezing Symptom — 1; 1 sneezes
Phase 2 N=21 A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
Allergic Rhinitis
Primary: Minimum Cross-Sectional Area (Amin) Proportion Measured Using Acoustic Rhinometry — 0.760; 0.742; 0.717; 0.795 ratio — p=0.302
Phase 3 N=715 Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies
Seasonal Allergic Rhinitis · SAR
Primary: Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment — -1.9…